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b Ludwig-Maximilians-Universität München, Department Biology I, Plant Evolutionary Cell Biology, Planegg-Martinsried, GermanyThe high costs of novel drug development and ﬁnancial risks linked Patient-stratiﬁcation and model reconstruction based on patient or
to failures in clinical trials, has led pharmaceutical companies to search
for new indications for already approved and well-studied drugs with
known side effects. This process known as drug repurposing or drug re-
positioning accounted for 20% of all drugs released in 2013 in the US. In
the recent years, metabolic modelling approaches have been success-
fully used to predict drug targets and drugs for repurposing [1] by sim-
ulating the effect of thousands of drugs on various cancer types while
also predicting potential side effects [2].
The ﬁrst metabolicmodels that have been used for drug repurposing
were generic cancer models or generic disease models that integrated
and combined data from different samples and cell lines. These consen-
sus models allowed ﬁnding novel drug targets primarily in the central
carbon system [1] that has been highly conserved across most cancer
types or tumors of a same type.
Since then, the advent of very efﬁcient model-building algorithms
[3–5] and the increase of the reconstructed model's robustness and res-
olution power (capacity to capturemetabolic variations between differ-
ent conditions and contexts) enables to consider the reconstruction of
personalised metabolic models for patients in order to predict tailored
repositioned drug treatments [6].
The question remains to be answered whether building patient-
speciﬁc or consensus cancer-type/generic models for drug response
prediction is the optimal strategy. Both approaches have their caveats
and advantages. In the article of EBioMedicine [7], Turanli and colleagues
opted for the reconstruction of a consensus prostate cancer model from
N450 personalised models because the patient-speciﬁc models showed
a large variability in the number of reactions and associated genes,
which might be explained by the inherent cancer heterogeneity.
When talking about cancer heterogeneity, one distinguishes between
inter-tumor and intra-tumor heterogeneity. A priori, the high inter-
tumor heterogeneity advocates against the building of consensus
models as many cancers such as breast, colorectal, and prostate cancer
show different molecular subtypes based on the tumor mutation state
that have a predictive factor in regard of therapeutics efﬁciency.DOI of original article: https://doi.org/10.1016/j.ebiom.2019.03.009.
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ﬁciency drugs for the given patient group that might have only a low or
no effect for other patient groups. For example, if a patient shows a spe-
ciﬁc tumor mutation, personalised models can be used to ﬁnd novel
drugs and drug targets that would have been missed otherwise and
therefore could greatly beneﬁtting the patients. Furthermore, generic
models are more likely to predict already known drug targets while fo-
cussing on well-conserved and intensively studied reactions signatures.
However, when considering the intra-tumor heterogeneity, which does
not take into account the molecular subtyping or personalised models,
ﬁnding more generic drugs that would have an effect on a wider spec-
trumof cancer cells could reduce the risk of selecting for resistant cancer
clones. In addition, personalisedmodels have a higher resolution power
and, therefore, are more likely to unravel new drug targets but are less
robust to noise than generic models.
Even though,metabolic modelling has been successfully used to dis-
cover new drug targets while the model quality has greatly improved
over the last couple of years, there are some important challenges to
keep in mind. First off, a context speciﬁc model is only as good as the
original input model [8]. Most input models should be qualiﬁed as a re-
construction rather than amodel. Models can be readily used formodel-
ling purposes and can be obtained from a global reconstruction whose
attempt it is to be as complete as possible in terms of known reactions,
genes, and metabolites. Because reconstructions incorporate many re-
action that are not simultaneously active in a cell, they are prone to
the existence of loops [9] that would hinder downstream analysis.
Moreover, the accuracy, resolution power, and noise robustness of a
metabolic model is highly variable and strongly depended on the
context-speciﬁc model building algorithm as well as on data pre-
processing and integration [10].
Although, personalised models can capture the intra-tumor hetero-
geneity, the high inter-model variance can, to some extent, be explained
by the bias introduced from the context-speciﬁc model-building algo-
rithm used, batch effects, or the setting of arbitrary thresholds during
data integration. While metabolic modelling and personalised models
have the potential to be routinely used by pharmaceutical companies
for drug discovery and drug repurposing, more throughout and system-
atic benchmarking of context-speciﬁc models, algorithms as well
as the prepossessing and integration workﬂow of proteomic and
transcriptomic data into genome-scale metabolic reconstructions willthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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models.
Taken together, the work of Turanli and colleagues [7] describes
an innovative workﬂow for the integration of proteomic and
transcriptomic data that allows dealing with the high heterogeneity in
cancer. By using a consensus model as canvas for the integration of dif-
ferentially expressed genes, reporter metabolites, and drug signatures
obtained from CMap2, drugs that could potentially reverse the gene ex-
pression in prostate cancer have been predicted. One of the predicted
drugs, Ifenprodil, was shown to inhibit the growth of a prostate cancer
cell line in vitro.
Disclosure
The authors declared no competing interests.
References
[1] Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. Predicting selective drug
targets in cancer through metabolic networks. Mol Syst Biol 2011;7(1):501.
[2] Shaked I, Oberhardt MA, Atias N, Sharan R, Ruppin E. Metabolic network prediction
of drug side effects. Cell Syst 2016 Mar;2(3):209–13 Internet. Available from http://
linkinghub.elsevier.com/retrieve/pii/S2405471216300734.Please cite this article as: M.P. Pacheco, T. Bintener and T. Sauter, Towar
speciﬁc metabolic models, EBioMedicine, https://doi.org/10.1016/j.ebiom[3] Vlassis N, Pacheco MP, Sauter T. Fast reconstruction of compact context-speciﬁc
metabolic network models. In: Ouzounis CA, editor. PLoS Comput Biol, 10(1). 2014
Jan 16. p. e1003424 Internet. Available from http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=3894152&tool=pmcentrez&rendertype=abstract.
[4] Pacheco MP, John E, Kaoma T, Heinäniemi M, Nicot N, Vallar L, et al. Integrated met-
abolic modelling reveals cell-type speciﬁc epigenetic control points of the macro-
phage metabolic network. BMC Genomics 2015;16(1):809.
[5] Yizhak K, Gaude E, Le Dévédec S, Waldman YY, Stein GY, van de Water B, et al.
Phenotype-based cell-speciﬁc metabolic modeling reveals metabolic liabilities of
cancer. Elife 2014 Nov 21;3(November):1–23 Internet. Available from https://doi.
org/10.7554/eLife.03641.
[6] Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J. Identiﬁcation of an-
ticancer drugs for hepatocellular carcinoma through personalized genome-scale
metabolic modeling. Mol Syst Biol 2014 Mar 28;10(3):721 Internet. Available from
https://doi.org/10.1002/msb.145122.
[7] Turanli B, Zhang C, Kim W, Benfeitas R, Uhlen M, Yalcin K, et al. Discovery of thera-
peutic agents for prostate cancer using genome-scale metabolic modeling and drug
repositioning. EBioMedicine 2019. https://doi.org/10.1016/j.ebiom.2019.03.009 In-
ternet. Available from.
[8] Swainston N, Smallbone K, Hefzi H, Dobson PD, Orellana CA, Thomas A. Recon 2.2:
from reconstruction to model of human metabolism; 2016.
[9] Pfau T, Pacheco MP, Sauter T. Towards improved genome-scale metabolic network
reconstructions: uniﬁcation, transcript speciﬁcity and beyond. Brief Bioinform
2015 Nov 28:bbv100 Internet. October. Available from https://doi.org/10.1093/bib/
bbv100.
[10] Pacheco MP, Pfau T, Sauter T. Benchmarking procedures for high-throughput con-
text speciﬁc reconstruction algorithms. Front Physiol 2016;6(6):1–19 Internet. Jan
22. Available from https://doi.org/10.3389/fphys.2015.00410/abstract.ds the network-based prediction of repurposed drugs using patient-
.2019.04.017
